{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:38:17Z","timestamp":1784273897485,"version":"3.55.0"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In recent years, the incidence of pertussis has been increasing globally. The high prevalence of macrolide-resistant strains has led to a significant rise in both pertussis cases and associated mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This retrospective study aimed to evaluate the clinical effectiveness and safety of compound sulfamethoxazole (SMZco) vs. macrolides in pediatric pertussis treatment under real-world clinical conditions, providing evidence for its clinical application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were divided into macrolide and SMZco groups based on treatment regimens. Comparative analyses included overall treatment effectiveness, duration of nocturnal coughing, paroxysmal coughing, post-tussive vomiting, hospitalization length, and adverse drug reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The macrolide group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923) showed 3 markedly effective, 8 effective, and 12 ineffective cases (total effectiveness rate 47.8%). The SMZco group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200979) demonstrated 26 markedly effective, 38 effective, and 15 ineffective cases (total effectiveness rate 81.0%), with significantly superior effectiveness vs. macrolides (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). The SMZco group exhibited statistically significant reductions in hospitalization duration (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05), paroxysmal coughing (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05), post-tussive vomiting (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05), and nocturnal coughing (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). Gastrointestinal adverse events occurred in 8 macrolide-treated patients vs. 6 SMZco-treated patients (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). Rash was observed in 12 SMZco-treated cases but none in the macrolide group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SMZco significantly improves treatment effectiveness, shortens symptom duration and hospitalization, and reduces economic burden in pediatric pertussis. These findings position SMZco as an effective and safe alternative, particularly in regions with high macrolide resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1622467","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T06:30:42Z","timestamp":1765261842000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Compound sulfamethoxazole for pediatric pertussis: a retrospective cohort study in a region with high macrolide resistance"],"prefix":"10.3389","volume":"13","author":[{"given":"Lin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taohong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ram.2020.07.001","article-title":"Bordetella pertussis, a reemerging pathogen in pediatric respiratory infections. A study in Quito, Ecuador","volume":"53","author":"V\u00e1sconez","year":"2021","journal-title":"Rev Argent Microbiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1017\/S0950268820000102","article-title":"Evaluation of immunisation strategies for pertussis vaccines in Jinan, China\u2014an interrupted time-series study","volume":"148","author":"Liu","year":"2020","journal-title":"Epidemiol Infect"},{"key":"B3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3201\/eid3001.221588","article-title":"Molecular evolution and increasing macrolide resistance of Bordetella pertussis, Shanghai, China, 2016\u20132022","volume":"30","author":"Fu","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3201\/eid2512.181836","article-title":"High prevalence of macrolide-resistant Bordetella pertussis and ptxP1 genotype, mainland China, 2014\u20132016","volume":"25","author":"Li","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3390\/antibiotics11111570","article-title":"Macrolide resistance in Bordetella pertussis: current situation and future challenges","volume":"11","author":"Ivaska","year":"2022","journal-title":"Antibiotics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"106835","DOI":"10.1016\/j.ijantimicag.2023.106835","article-title":"Domination of an emerging erythromycin-resistant ptxP3 Bordetella pertussis clone in Shanghai, China","volume":"62","author":"Cai","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"B7","doi-asserted-by":"publisher","first-page":"106140","DOI":"10.1016\/j.jinf.2024.106140","article-title":"Resurgence and atypical patterns of pertussis in China","volume":"88","author":"Mengyang","year":"2024","journal-title":"J Infection"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2389086","DOI":"10.1080\/22221751.2024.2389086","article-title":"Rising pertussis cases and deaths in China: current trends and clinical solutions","volume":"13","author":"Yahong","year":"2024","journal-title":"Emerg Microbes Infec"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3760\/cma.j.cn112137-20240124-00179","article-title":"[Guidelines for diagnosis and management and prevention of pertussis of China (2024 edition)]","volume":"104","year":"2024","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/INF.0000000000002911","article-title":"Effect of macrolides and \u03b2-lactams on clearance of Bordetella pertussis in the nasopharynx in children with whooping cough","volume":"40","author":"Mi","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"B11","first-page":"691","article-title":"Comparison of macrolide resistance, molecular characteristics and MAST types of Bordetella pertussis collected from Xi'an and Shanghai","volume":"43","author":"Zhang","year":"2022","journal-title":"J.Xi'an Jiaotong Univ (Medical Sciences)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"614","DOI":"10.16766\/j.cnki.issn.1674-4152.003463","article-title":"Effect observation of compound sulfamethoxazole in the treatment of pertussis in children","volume":"22","author":"Wang","year":"2024","journal-title":"Chin J Gen Pract"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1622467\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T06:30:43Z","timestamp":1765261843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1622467\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":12,"alternative-id":["10.3389\/fped.2025.1622467"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1622467","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"article-number":"1622467"}}